Could a stomach hormone help people with leg artery disease walk farther?
NCT ID NCT04377126
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether daily injections of unacylated ghrelin, a natural hormone, can improve walking ability in people aged 55 and older with peripheral artery disease (PAD). Participants receive either the hormone or a placebo for four months. The study measures changes in how far they can walk in six minutes, aiming to see if the treatment boosts blood flow and muscle function in the legs.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
unacylated ghrelin
What this could lead to
If it works, this could point toward a new treatment to help people with PAD walk farther and maintain mobility.
What could go wrong
This is a small, early-phase pilot trial. The results may not confirm benefit, and the treatment may not work for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERIPHERAL ARTERY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Northwestern University Feinberg School of Medicine
Chicago, Illinois, 60611-3008, United States
-
University of Chicago
Chicago, Illinois, 60637, United States